MADISON, NJ--(Marketwired - Jan 15, 2014) - Reimbursement Intelligence (RI), an information and marketing services firm that provides expert insights and solutions about the changing healthcare reimbursement environment to biopharma, device, and diagnostic companies, announced today a number of executive appointments and the launch of 3 exciting proprietary new research and information products. Taken together these actions represent a major step forward in making RI one of the leading healthcare service firms focused on market access and reimbursement.


Norman C. Selby has become CEO of Reimbursement Intelligence. Norman brings over 30 years of experience in healthcare to RI. He founded and ran McKinsey & Co.'s Global Pharmaceuticals and Medical Products Practice starting in the late 1980s, and since then has successfully built and sold 3 different healthcare companies (TransForm Pharmaceuticals, Windhover Information, and Physicians Interactive LLC). Norman is also on the Board of Directors of Infinity Pharmaceuticals (INFI), Metamark Genetics, Merz Group GmbH, and Memorial Sloan Kettering Cancer Center. Norman has a BA from Yale University and an MBA from Harvard Business School. He is currently chairman of Real Endpoints LLC, RI's corporate parent.

Susan Raiola is promoted to Co-President of Reimbursement Intelligence. Susan is head of RI's Training and Communications Division, which focuses on creating customer-specific solutions and tools to improve the Reimbursement IQ™ and productivity of marketing and sales personnel across a client's organization. She is a graduate of Seton Hall, has been at RI for five years, and is a recognized leader in bringing best practices and an innovative approach to training and communication that addresses reimbursement challenges and opportunities.

John Whang, MD, FACC is promoted to Co-President of Reimbursement Intelligence. John is head of RI's Market Research Division, which provides both syndicated and custom research about reimbursement and access issues of importance to executives. John is a graduate of Harvard College, has an MD from Columbia University, is a board-certified cardiologist, and was at McKinsey before joining RI in 2012.

Rhonda Greenapple, RI's founder, has decided to leave the company to pursue other interests.


RI provides a wide range of syndicated reports and custom services that span market research, training, and communications. It is pleased to add three new offerings to its portfolio.

Rx Scorecard: The first and only tool that comprehensively assesses the value -- from a payer's perspective -- of all drugs in a therapeutic indication. It measures and integrates a total of 19 factors that cover efficacy, safety, use/convenience, adherence, price, health outcomes, and cost offsets to determine the relative value of your drug vs. competition -- and potential actions to improve value. Learn more

Pathway Tracker: A syndicated information product that identifies and tracks the critical drivers that influence the use of branded drugs at the various treatment points in a clinical pathway. Results lead to brand-specific recommendations to enhance product access. Learn more

RiQ: A comprehensive training program that ensures your customer-facing teams are exceptional in their ability to address key customer needs and to drive improved sales performance. The program includes a quantitative assessment of field skills and execution using customer and internal input, a gap analysis that identifies high priority needs, and a training program that targets those areas of greatest opportunity. Learn more

Commenting on these changes, Norman Selby, RI's CEO, said, "RI has been providing actionable insights and solutions around reimbursement for several years. Our expanded management team and the launch of these new products significantly strengthen our capability to work with our clients to address the growing importance and complexity of their reimbursement and market access challenges. Susan and John are highly creative and experienced -- critical advantages to our clients given how quickly reimbursement practices are changing and having greater impact on commercial success. We are delighted to have them helping to lead RI. We also thank Rhonda for contributions to RI's success and growth, and wish her well."


RI is a pioneering leader in delivering pharmaceutical, biotech, diagnostic, and medical device professionals the research and tools they need to navigate the ever-changing reimbursement landscape. Founded in 2005, RI was formed in response to the growing demand for streamlined reimbursement strategies that would better connect patients, payers, and healthcare providers to our clients' innovations.

Contact Information:


Jessica DiPaolo
VP, New Business Development

Theresa Penyak
VP, New Business Development